How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
UAE Pharmaceuticals Market, By Region, Competition, Forecast and Opportunities, 2029F
September 20, 2024 04:53 ET
|
Research and Markets
Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "UAE Pharmaceuticals Market, By Region, Competition, Forecast and Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's...
Western Blotting Market Is Expected To Generate Revenue Of USD 2,620.2 Mn By 2033, At 6.8% CAGR: Dimension Market Research.
September 18, 2024 12:15 ET
|
Dimension Market Research
New York, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Overview The Global Western Blotting Market is expected to reach USD 1,455.4 million in 2024 which is further projected to grow up to USD 2,620.2...
[Latest] Global Sanitary Pumps and Valves Market Size/Share Worth USD 3.1 Billion by 2033 at a 3.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
September 17, 2024 13:00 ET
|
Custom Market Insights
Austin, TX, USA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Sanitary Pumps and Valves Market Size, Trends and Insights By Type...
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 17, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2024
September 16, 2024 12:44 ET
|
Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi: Information concerning the total number of voting rights and shares - August 2024
September 16, 2024 12:44 ET
|
Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
Saudi Arabia $13.99 Bn Pharmaceutical Market Trends, Competition, Forecast & Opportunities, 2029F
September 16, 2024 10:46 ET
|
Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Saudi Arabia Pharmaceutical Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
India Pharmaceutical Industry Research 2024: $105+ Billion Market Trends, Regional Insights, Competition, Forecasts and Opportunities, 2020-2030
September 11, 2024 11:50 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Pharmaceutical Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024 01:04 ET
|
Regeneron Pharmaceuticals, Inc.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in...